Roche’s ovarian cancer treatment Avastin gets European approval
The approval in the European Union (EU) was based on results of the Phase III Aurelia trial which included women with recurrent, platinum-resistant ovarian cancer who received either
XtalPi has entered a strategic partnership valued at more than $400m with an international biopharmaceutical company to develop oral small-molecule therapeutics targeting a G protein-coupled receptor (GPCR).
Kadimastem will utilize its unique platform for Merck Serono, the biopharmaceutical division of Merck, for the screening of new compounds as potential new therapeutics. Kadimastem has developed a